General Injectables & Vaccines, Inc. - תוצאות חיפוש

pfizer pharmaceuticals israel ltd - sirolimus - תמיסה (פומי) - sirolimus 1 mg/ml - sirolimus - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.

ישראל - עברית - Ministry of Health

לוותרים תמיסה

trima israel pharmaceutical products maabarot ltd - levetiracetam - תמיסה (פומי) - levetiracetam 100 mg/ml - levetiracetam - levetiracetam - levetrim solution is indicated as:- monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy. - adjunctive therapy:in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy.in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy

ישראל - עברית - Ministry of Health

פייקומפה 2 מג טבליות מצופות

eisai israel ltd., israel - perampanel as anhydrous - טבליות מצופות פילם - perampanel as anhydrous 2 mg - perampanel - perampanel - fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older.

ישראל - עברית - Ministry of Health

פייקומפה 4 מג טבליות מצופות

eisai israel ltd., israel - perampanel as anhydrous - טבליות מצופות פילם - perampanel as anhydrous 4 mg - perampanel - perampanel - fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older.